➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Medtronic
AstraZeneca
McKinsey
Dow
Merck

Last Updated: August 13, 2020

DrugPatentWatch Database Preview

IOHEXOL - Generic Drug Details

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

What are the generic sources for iohexol and what is the scope of patent protection?

Iohexol is the generic ingredient in ten branded drugs marketed by Interpharma Praha As and Ge Healthcare, and is included in three NDAs. Additional information is available in the individual branded drug profile pages.

There are three drug master file entries for iohexol. Three suppliers are listed for this compound.

Recent Clinical Trials for IOHEXOL

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
National Cancer Institute (NCI)N/A
Columbia UniversityEarly Phase 1
Vanderbilt University Medical CenterPhase 4

See all IOHEXOL clinical trials

Pharmacology for IOHEXOL
Medical Subject Heading (MeSH) Categories for IOHEXOL

US Patents and Regulatory Information for IOHEXOL

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Ge Healthcare OMNIPAQUE 140 iohexol INJECTABLE;INJECTION 018956-005 Nov 30, 1988 RX Yes Yes   Start Trial   Start Trial   Start Trial
Ge Healthcare OMNIPAQUE 240 iohexol SOLUTION;INJECTION, ORAL, RECTAL 018956-002 Dec 26, 1985 RX Yes Yes   Start Trial   Start Trial   Start Trial
Ge Healthcare OMNIPAQUE 350 iohexol SOLUTION;INJECTION, ORAL 018956-004 Dec 26, 1985 RX Yes Yes   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for IOHEXOL

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Ge Healthcare OMNIPAQUE 350 iohexol SOLUTION;INJECTION, ORAL 018956-004 Dec 26, 1985   Start Trial   Start Trial
Ge Healthcare OMNIPAQUE 300 iohexol SOLUTION;INJECTION, ORAL, RECTAL 018956-003 Dec 26, 1985   Start Trial   Start Trial
Ge Healthcare OMNIPAQUE 140 iohexol INJECTABLE;INJECTION 018956-005 Nov 30, 1988   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Harvard Business School
AstraZeneca
Mallinckrodt
Boehringer Ingelheim
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.